MapLight Therapeutics MPLT
NASDAQ MPLT
$13.86 +0.72 (+5.48%)
As of: Sep 4, 2026 · 2:31 PM EDT

MapLight Therapeutics (MPLT) Income from Continuing Operations (2024 - 2026)

MapLight Therapeutics (MPLT) posted Income from Continuing Operations of 81207000.0 for Q4 2025, down 138.36% sequentially from 34069000.0 in Q3 2025, and down 276.34% YoY from 46050948.62 in Q4 2024.

Analysis

MapLight Therapeutics (MPLT) Income from Continuing Operations (2024 - 2026) Analysis & Trends

MapLight Therapeutics has reported Income from Continuing Operations for 2 years, with the latest figure at 81207000.0 in Q4 2025.

  • Quarterly Income from Continuing Operations fell 276.34% year-over-year to 81207000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 156967000.0 (changed N/A YoY) and the FY2025 annual result came in at 176190000.0, down 93.77% from the prior year.
  • Income from Continuing Operations retreated to 81207000.0 in Q4 2025 per MPLT's latest filing, from 34069000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 20113000.0 in Q3 2024 and troughed at 81207000.0 in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Vertex Pharmaceuticals 138.77 Bn 130.92 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.51 Bn 77.52 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn 601.00 Mn
4 Moderna 58.20 Bn 53.06 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.04 Bn 44.04 Bn - -644.37 Mn
6 BeOne Medicines 39.99 Bn 34.89 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.45 Bn 32.14 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.40 Bn 27.56 Bn - 81.49 Mn
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn -13.27 Mn
10 MapLight Therapeutics 629.68 Mn 629.68 Mn - -61.20 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -61.20 Mn
Dec 31, 2025 -80.91 Mn
Sep 30, 2025 -29.95 Mn
Jun 30, 2025 -29.98 Mn
Dec 31, 2024 -21.88 Mn
Sep 30, 2024 -19.81 Mn